Reflecting on 2024: a category sweep of the Nobels, AI enabled clinical readouts, and the first trillion dollar pharma in sight. We stand on the shoulders of giants. Looking to 2025: This is just the beginning. Make no small plans.

@_DimensionCap's research team will be at the @KeystoneSymp symposium on AI + Molecular Biology on Sept. 15th in Sante Fe. If you're there and would like to meet up, DM me or my colleague @bauer_lesavage. Hope to see you there!

Central nervous system (CNS) disorders are the leading cause of disease burden worldwide. Collectively, they affect 43% of the global population and are responsible for 443M disability adjusted life years (i.e. years lost to disability or premature death) each year. However,

We’ve been spending a lot of time recently in neurology. It’s a space in dire need of novel targets and drug mechanisms. Check out @bauer_lesavage’s newest essay on why neuro is so hard and what learnings we can reapply from biotech’s recent successes in immunology.

cannot wait for the next 12 months @viswacolluru and the entire @lifeschemistry team!!

in the last 12 months Enveda has 1. entered the clinic w soon to be 3 new molecules 2. followed the science pursuing medicines with decacorn potential whilst altering billions of global lives 3. added Mikael Dolsten, former CSO of Pfizer, to the board 4. become a biotech unicorn

RT @zavaindar: i'd use this space to talk about Dimension portco @newlimit but having just watched the below w @jacobkimmel & @dwarkesh_sp…

🧬 Dr. Mikael Dolsten is joining the @ChaiDiscovery board! In 15 years as @Pfizer's Chief Scientific Officer he: ⚛️ Progressed 150 molecules to clinical trials 💊 Delivered 36 approved medicines, from vaccines to cancer therapies

.@dwarkesh_sp has a rare talent for traversing the tree of ideas by stepping upon only the most entropic branches it was a joy to discuss ideas around AI in bio, human evolution, the biology of aging, @newlimit, & the future of therapeutics a few weeks back

“Convoke’s platform functions as an information and analysis operating system for life sciences, built to turn raw knowledge into the deliverables that drive critical decisions” Congrats @Convokebio team on the launch! Let’s build! 💪🏻💪🏻

Customers are already logging multi-hour *daily* usage sessions and this is just the beginning. If you are interested to work on cutting-edge AI tooling in a massive industry, they are hiring:

Congrats on the launch of most recent @_DimensionCap co @Convokebio! @Atelfo @okaymaged and @VelagapudiVikas are an incredible team building an AI operating system for life science. From data ingestion, to clinical insights, to program tracking, Convoke allows customers to

we led the @newlimit series A in 2023, and every board meeting with @jacobkimmel i come out with my mind absolutely blown i have to imagine Dwarkesh's pod w Jacob will have the exact same result for many many thousands of people

Not just another job! A rare window to shift the frontier of science 🤫🧬

You can read more about our fundraise and mission in our blog here:

We've raised $8.6m to build leading AI tools for the biopharma industry! Our seed financing was led by @kleinerperkins and @_DimensionCap , with participation from @ACME, @CommaCapital, @Liquid2V, @notboringco, @AudaciousHQ, @Lux_Capital, and leaders in AI and biotechnology

Deep Tech Software Engineer:

ML X Protein Modeling:

ML X Physics:

a few months ago we @_DimensionCap quietly funded a team of 3 MIT computer scientists & mathematicians at the forefront of ML & physics+simulation for enzyme design. these. guys. are. cracked today they're stealthily building the early team. if you're world class, look below 👇

i've never seen such a wide dispersion between the cutting edge & the status quo. @chaidiscovery's tech (choose target(s), choose epitope(s) -> in-silico design a binder) will ultimately diffuse across the ecosystem. until then, the below is a sneak peek https://t.co/iTKCzUHr7l